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Abstract. In May of 2010, two communities (Truenococha and Santa Marta) reported to be at risk of vampire bat
depredation were surveyed in the Province Datem del Marañón in the Loreto Department of Perú. Risk factors for bat
exposure included age less than or equal to 25 years and owning animals that had been bitten by bats. Rabies virus
neutralizing antibodies (rVNAs) were detected in 11% (7 of 63) of human sera tested. Rabies virus ribonucleoprotein
(RNP) immunoglobulin G (IgG) antibodies were detected in the sera of three individuals, two of whom were also
seropositive for rVNA. Rabies virus RNP IgM antibodies were detected in one respondent with no evidence of rVNA
or RNP IgG antibodies. Because one respondent with positive rVNA results reported prior vaccination and 86% (six of
seven) of rVNA-positive respondents reported being bitten by bats, these data suggest nonfatal exposure of persons to
rabies virus, which is likely associated with vampire bat depredation.
INTRODUCTION
Rabies is caused by single-stranded negative-sense RNA
viruses in the genus Lyssavirus. Rabies virus (RABV; geno-
type I) is the most prolific of the 12 viral species classi-
fied within the genus, and it is responsible for greater than
55,000 human deaths annually.1 Typically, RABV is transmit-
ted in the saliva after the bite of an infected mammal. In the
Americas, bats and carnivores are the major reservoirs of
RABV.2 Multiple insectivorous bat species play a role in
RABV transmission to humans in the United States.3 In Latin
America, RABV is transmitted principally by the common
vampire bat (Desmodus rotundus), although several other
Neotropical bat species play a role in RABV circulation.4–8
Rabies is the most recognized human health risk from bats in
Latin America, with dual impacts for public health and agri-
culture.9 Wide circulation of RABV among vampire bats
throughout their geographic range is shown by extensive
reports of vampire bat-associated RABV infections in bats,
humans, and cattle throughout Latin America.8,10–12
In Perú, outbreaks of rabies linked to vampire bat bites
have been documented among populations living in the
Amazon region over the past several decades.4,12–14 Approxi-
mately 81% (113 of 139) of the human rabies cases reported
in Perú from 1996 to 2010 were associated with vampire
bats.12,15 In April of 1996, an outbreak of rabies resulted in at
least nine human deaths in two Amazonian villages. Samples
from the victims were characterized as RABV associated with
D. rotundus.13 Between December of 2006 and February of
2007, an outbreak involving 527 persons bitten by vampire
bats claimed at least 23 deaths in southeastern Perú, all impli-
cating D. rotundus.4 In 2009, 19 cases of human rabies trans-
mitted by vampire bats were reported from five outbreaks
located in the Amazon region.16–18 From December of 2009
to February of 2011 in the District of Nieva, 14 suspected
human rabies deaths were reported, and two of the cases were
confirmed by direct fluorescent antibody testing.19 Most
recently, from February to July of 2011, at least 20 suspected
human rabies cases (18 children and 2 adults) among indige-
nous persons from the Aguaruna tribe in the District of Imaza
were reported.20 Common risk factors for human RABV
infection in the Amazon include poor housing conditions,
small population groups in remote areas, poor access to
health services, and a general lack of awareness or cultural
barriers regarding the transmission of rabies by bats. There is
ample evidence of frequent depredation by vampire bats on
humans and livestock in the Peruvian Amazon but inadequate
investigation of human response to RABV exposures among
persons at risk living in this region.
Rabies has the highest case fatality rate of any conventional
infectious disease, approaching 100%. The likelihood of a
productive rabies infection after exposure to a lyssavirus is
known to depend on a variety of factors, including but not
limited to dose, route of exposure, site of exposure, variant,
host genetic makeup, pre- and/or post-exposure prophylaxis
(PreEP and PEP, respectively), etc.21 All mammals are sus-
ceptible to lyssavirus infection, but species-level variation in
susceptibility has long been recognized.2 Among reservoir
species, foxes and other canids seem to be quite susceptible
to RABV infection, characterized by little to no (e.g., 0–5%)
rabies virus neutralizing antibody (rVNA) seroprevalence
(i.e., animals developing virus neutralizing antibodies after
RABV exposure) among natural populations.22,23 Contrast-
ingly, bat populations seem to be less susceptible to RABV
infection and are characterized by relatively high (e.g., 5–
50%) rVNA seroprevalence in the wild.24–26 One experiment
suggested that non-human primates might be resistant to
infection from rabid bats,27 but bat-associated human rabies
deaths worldwide show human susceptibility to lyssavirus
infection by bat bite.3,28–30 The work by Bell31 argued provoc-
atively that abortive RABV infections were readily observed
and reproducible in animals, and thus, they should be consid-
ered a possible outcome for humans. Reports of human sur-
vival after rabies infection, despite clinical presentation, are
quite rare in the literature.32–37 However, a recent case of
presumed abortive rabies infection in the United States high-
lights a rare event of human survival after presentation of
clinical symptoms and minimal intervention treatment.38
The objective of this study was to investigate risk factors for
bat and RABV exposure in Amazonian communities that
were suspected to be at high risk of vampire bat depredation
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based on their proximity to recent outbreaks in Perú and rural
living conditions. A survey questionnaire was used to capture
demographic information of the study populations, salient
details of any previous bat exposure, and self-reported vacci-
nation history among respondents sampled.
MATERIALS AND METHODS
Sample collection. Two communities were surveyed in May
of 2010 in the Province Datem del Marañón in the Loreto
Department of Perú (Figure 1). Samples were collected as
part of a survey to evaluate bat–human interactions and
rabies risk in the Amazon. The survey protocol was approved
by the Centers for Diseases Control and Prevention (United
States) and the Hospital Nacional Dos de Mayo (Perú) Insti-
tutional Review Boards in compliance with all applicable fed-
eral regulations governing the protection of human subjects.
Both communities could only access the nearest health post
in the town of San Lorenzo by river. The community of
Truenococha is in the District of Pastaza, had an estimated
population of 111, is of mestizo (i.e., mixed) cultural descent,
is approximately 2 hours from the nearest health post by
motorized boat (~50 km), and was raising approximately
12 head of cattle at the time of the study. The community of
Santa Marta is in the District of Cahuapanas, had an esti-
mated population of 205, is of indigenous cultural descent, is
located approximately 6–8 hours from the nearest health post
by motorized boat (~85 km), and was not raising any cattle at
the time of the study. Residents from both communities were
enrolled in a knowledge, attitudes, and practices (KAP) sur-
vey about prior bat exposure, health-seeking behaviors,
knowledge of rabies, and prior rabies PreEP or PEP. A 2- to
5-mL blood sample was collected from consenting respon-
dents by an aseptic technique. Sera were separated by centri-
fugation, stored in liquid nitrogen until transfer to +80°C,
and shipped from Perú to the Centers for Disease Control
and Prevention in Atlanta, Georgia.
rVNA. Sera were screened for rVNA by the rapid fluores-
cent focus inhibition test (RFFIT) as described.39 Briefly, sera
were screened individually at a 1:5 and 1:25 dilution against a
constant dose of rabies virus (50 focus forming doses [FFD50]).
Sera that exhibited complete neutralization of RABV at a
1:5 dilution were considered rVNA positive using the recom-
mendations of the Advisory Committee on Immunization
Practices (ACIP).21 Sera that were rVNA positive were
screened at additional dilutions up to 1:390,625 to determine
Figure 1. Map of the study location with the triangles indicating the communities surveyed and the circles with stars indicating the locations of
previous human rabies outbreaks associated with vampire bats.
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endpoint titers using the Reed–Muench method.40 These data
were converted to international units per milliliter−1 by com-
parison with the US Standard Rabies Immune Globulin
(SRIG; Laboratory of Standards and Testing, Food and Drug
Administration, USA) diluted to 2 IU mL−1.
Indirect fluorescent antibody assay. Sera were screened for
RABV ribonucleoprotein (RNP) immunoglobulin M (IgM)
and IgG antibodies by the indirect fluorescent antibody (IFA)
test as described41 using affinity-purified, fluorescein-labeled
goat anti-human antibodies (Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, MD). Sera were screened individually at
dilutions of 1:4 to 1:128 with IgM or IgG preparations, respec-
tively. A positive reaction at any of these dilutions was consid-
ered evidence of RABV-specific IgM or IgG antibodies.
Statistical analyses. Separate analyses were conducted with
survey data. The first analysis stratified all respondent data by
exposure history to bats (i.e., with exposure defined as a bat
bite or scratch or touching a bat with unprotected skin) to
evaluate risk factors for bat exposure. The second analysis
focused only on individuals from whom a serum sample was
obtained and tested, with stratification of respondent data
regarding bat exposure by serological status to evaluate risk
factors for rabies virus exposure. All statistical analyses were
performed using SAS v.9.3 (SAS Institute, Cary, NC). Fisher
exact test was used to evaluate associations (a = 0.05)
between the response (stratification) variable (i.e., bat expo-
sure or serological status) and factors such as community of
residence, age, sex, education level, and self-reported bat expo-
sure history, which includes subcategories of bite, scratch, and/
or touching a bat with unprotected skin.
RESULTS
A total of 92 persons were interviewed from 51 households
and represented a total community population of 316 persons
(Table 1). The mean age of all respondents was 25 years
(range = 2–67 years), and 55% (51 of 92) of respondents
were male. Among respondents, 82% (62 of 76) of persons
interviewed reported completing a primary education or less.
Among households, 86% (44 of 51) owned pets or live-
stock, and 61% (27 of 44) of households owning pets or live-
stock reported that their animals were bitten by bats. Among
the total community population, 23% (73 of 316) of persons
had exposure to bats. Although a biased sample, among
persons interviewed, 54% (50 of 92) reported being bitten by
bats previously.
Among the surveyed populations, several risk factors for
exposure to bats were identified (Table 2). The most signifi-
cant risk factor for exposure to bats was community of resi-
dence, with Santa Marta having a greater proportion of
exposed persons (odds ratio [OR] = 8.71, P < 0.001). Other
significant factors included age, with persons aged 25 years or
younger having a greater risk of bat exposure (OR = 3.59, P =
0.038), and households reporting pets or livestock bitten by
bats (OR = 8.83, P < 0.001). Furthermore, households with
more than five family members (OR = 3.41, P = 0.03) were at
higher risk of bat exposure. Contrastingly, persons who
reported living at their house for less than 1 year were at a
lower risk for bat exposure compared with other respondents
(OR = 0.20, P = 0.02).
Among 63 sera obtained from individual respondents (age
range = 2–62 years, mean = 29 years; overall male to female
ratio is 1.85), 11% (7 of 63) showed an rVNA titer (range =
0.1–2.8 IU mL−1). From the IFA test, RABV RNP IgM and
IgG antibodies were detected from 4 of 63 samples (Table 3).
The rVNA seroprevalence was lower in Truenococha (5%; 1
of 19) compared with Santa Marta (14%; 6 of 44), contrasting
the trend in IFA antibody seroprevalence in Truenococha
(11%; 2 of 19) and Santa Marta (5%; 2 of 44). Among sero-
positive respondents from either community, all (9 of 9)
Table 1
Demographic and population characteristics of the two communities surveyed in the Province Datem del Marañón of Perú, 2010
Category Santa Marta Truenococha Total
Households visited 29 25 54
Households enrolled (percent of total visited) 28 (96.6%) 23 (92.0%) 51 (94.4%)
Individuals interviewed 68 24 92
Estimated community population (sum of persons reported living in each household) 205 111 316
Mean age in years (range) 21.3 (2–49) 35.6 (5–67) 25.0 (2–67)
Median age in years (range) 21.5 (2–49) 30.5 (5–67) 25.5 (2–67)
Male (percent of total interviewed) 35 (51.5%) 16 (66.7%) 51 (55.4%)
Education (N = 76)
Primary or below 44 (84.6%) 18 (75.0%) 62 (81.6%)
Secondary or above 8 (15.4%) 6 (25.0%) 14 (18.4%)
Households with pets or livestock (percent of households) 26 (92.9%) 18 (78.3%) 44 (86.3%)
Households with pets or livestock bitten by bats (percent of households with pets or livestock) 19 (73.1%) 8 (44.4%) 27 (61.4%)
Households with one or more bat exposures* (percent of households) 25 (89.2%) 11 (47.8%) 36 (70.6%)
Individuals with one or more bat exposures* (percent of estimated community population) 61 (29.8%) 12 (10.8%) 73 (23.1%)
Bat bite (percent of total interviewed) 44 (64.7%) 6 (25.0%) 50 (54.3%)
Bat bite more than one time per year 18 (26.5%) 0 18 (19.6%)
Bat bite within the last 6 months 31 (45.6%) 1 (4.2%) 32 (34.8%)
Bat contact with unprotected skin (percent of total interviewed) 16 (23.5%) 9 (37.5%) 25 (27.2%)
Skin contact more than one time per year 3 (4.4%) 4 (16.7%) 7 (7.6%)
Skin contact within the last 6 months 10 (14.7%) 5 (20.8%) 15 (16.3%)
Bat scratch (percent of total interviewed) 2 (2.9%) 1 (4.2%) 3 (3.3%)
Individuals reporting entering a bat cave or refuge (percent of total interviewed) 5 (7.4%) 6 (25.0%) 11 (12.0%)
Individuals reporting eating or cooking a bat as food (percent of total interviewed) 0 0 0
Rabies serology (N = 63)
RVNA positive (percent total tested) 6 (13.6%) 1 (5.3%) 7 (11.1%)
Any positive serology (percent total tested) 7 (15.9%) 2 (10.5%) 9 (14.3%)
*Defined as a bat bite, bat scratch, or bat contact with unprotected skin.
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reported bat exposure, which was defined as a bat bite,
scratch, or direct contact with unprotected skin. Furthermore,
75% (6 of 8) of unvaccinated seropositive respondents
reported a history of a bat bite (Table 3). Only one seropositive
respondent reported having received rabies PEP, although vac-
cination history details could not be elicited from two other
seropositive respondents.
Seropositive status of an individual was associated with age,
with persons aged 29 years or less being at significantly lower
risk of being seropositive (OR = 0.08, P = 0.01) (Table 4).
Seropositive status was not associated with community of res-
idence, gender, or education level. Although a greater pro-
portion of seropositive persons reported bat exposure (9 of 9;
100%), including bat bite (7 of 9; 78%) or touching a bat
Table 2
Risk factors for bat exposure among respondents in two communities in the Province Datem del Marañón of Perú, 2010
Subcategory
Exposed Non-exposed Total
P value OR (95% CI)n Percent n Percent n Percent
Demographics (N = 92)
Santa Marta 61 83.6 7 36.8 68 73.9 < 0.001* 8.71 (2.85–26.68)
Age less than or equal to 25 years{ 41 56.2 5 26.3 46 50.0 0.038* 3.59 (1.17–11.01)
Male 43 58.9 8 42.1 51 55.4 0.207 1.97 (0.71–5.48)
Household characteristics
More than five people living in household (N = 92) 52 71.2 8 42.1 60 65.2 0.029* 3.41 (1.20–9.65)
Own pets/livestock (N = 91) 63 87.5 17 89.5 80 87.9 1 0.82 (0.16–4.17)
Own dogs (N = 91) 24 33.3 11 57.9 35 38.5 0.065 0.36 (0.13–1.02)
Any pets/livestock bitten by bats (N = 79) 53 84.1 6 37.5 59 74.7 < 0.001* 8.83 (2.62–29.83)
Activities
Lived in this house less than 1 year (N = 73) 7 13.0 8 42.1 15 20.5 0.017* 0.20 (0.06–0.69)
More than 5 years living/working with bats (N = 53) 12 32.4 2 12.5 14 26.4 0.183 3.36 (0.66–17.21)
Reported hunting bats (N = 70) 6 11.8 1 5.3 7 10.0 0.665 2.40 (0.27–21.37)
Reported agriculture (N = 70) 43 84.3 17 89.5 60 85.7 0.717 0.63 (0.12–3.29)
Reported using a mosquito net (N = 70) 37 72.5 14 73.7 51 72.9 1 0.94 (0.29–3.11)
Education (N = 76)
Secondary or above 11 19.3 3 15.8 14 18.4 1 1.28 (0.32–5.16)
Knowledge (N = 70)
Reported having basic or no rabies knowledge 51 100.0 19 100.0 70 100.0 NA‡ NA
Indicated animal bites as mechanism of transmission 11 21.6 5 26.3 16 22.9 0.752 0.77 (0.23–2.61)
Described rabies as severe 19 37.3 8 42.1 27 38.6 0.785 0.82 (0.28–2.39)
Identified bats as a rabies source 8 15.7 4 21.1 12 17.1 0.723 0.70 (0.18–2.65)
Identified dogs as a rabies source 16 31.4 9 47.4 25 35.7 0.266 0.51 (0.17–1.49)
If bitten by a bat (N = 70)
Wash with soap and water 5 9.8 0 0.0 5 7.1 0.314 NA
Seek medical care 10 19.6 6 31.6 16 22.9 0.343 0.53 (0.16–1.74)
Do not know or do nothing 30 58.8 7 36.8 37 52.9 0.116 2.45 (0.83–7.26)
Other 6 11.8 6 31.6 12 17.1 0.074 0.29 (0.08–1.05)
If bitten by a rabid animal (N = 70)
Wash with soap and water 2 3.9 0 0.0 2 2.9 1 NA
Seek medical care 16 31.4 10 52.6 26 37.1 0.163 0.41 (0.14–1.21)
Do not know or do nothing 33 64.7 7 36.8 40 57.1 0.056 3.14 (1.05–9.39)
Other 0 0.0 1 5.3 1 1.4 0.195 0.18 (0.09–0.34)
Vaccinated against rabies (N = 92)
Post-exposure prophylaxis (bat exposure) 1 1.4 1 5.3 2 2.2 0.372 0.25 (0.015–4.19)
Pre-exposure prophylaxis (military service) 1 1.4 0 0.0 1 1.1 1 NA
*Statistically significant.
{Mean age of population.
‡NA = not applicable.
Table 3
Indication of bat exposure and prior pre- or post-exposure prophylaxis history among seropositive survey respondents
Gender (age in years) Location RFFIT (IU/mL)
IFA
Bat exposure* Bat bite PreEP/PEPIgG IgM
Male (48) Truenococha 0.4 1:128 – Yes No No
Male (54) Truenococha ct 1:128 – Yes Yes No
Male (34) Santa Marta 0.6 – – Yes Yes No
Male (40) Santa Marta < 0.05 – 1:8 Yes No nd
Female (49) Santa Marta 0.4 – – Yes Yes nd
Male (39) Santa Marta 2.8 – – Yes Yes No
Male (49) Santa Marta 0.4 – – Yes Yes No
Male (47) Santa Marta 0.6 – – Yes Yes No
Female (27) Santa Marta 0.1 1:8 – Yes Yes PEP
*Bat exposure defined as a bite, scratch, or direct contact with unprotected skin.
ct = cytotoxic; IFA = indirect fluorescent antibody; IU = international unit; Ig = immunoglobulin; nd = not determined; PEP = post-exposure prophylaxis; PreEP = pre-exposure prophylaxis;
RFFIT = rapid fluorescent focus inhibition test.
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(5 of 9; 56%), the differences were not significant compared
with the reported bat exposure of seronegative persons (36 of
48; 75%), including bat bite (31 of 48; 65%) or touching a bat
(16 of 48; 33%) (Table 4).
DISCUSSION
Despite a wealth of studies documenting natural seroprev-
alence among wildlife reservoirs, few prior studies have
reported natural human seroprevalence to RABV. One study
showed rVNA among 7% (2 of 30) of sera from raccoon
hunters in Florida, although at low titers (~0.1 IU mL−1).42
Another study, among Canadian Inuit hunters having animal
contact but no vaccination history for RABV, also detected
rVNA in 29% (9 of 31) of individuals.43 However, titers in
that study were also uniformly low (< 0.1 IU mL−1). A later
study among fox trappers in Alaska reported rVNA among
12% (3 of 26) of individuals.44 Two of three seropositive
trappers had a previous vaccination history. The single sero-
positive Alaska fox trapper who had not received rabies vac-
cine previously had a high rVNA titer (2.3 IU mL−1), perhaps
associated with a 47-year history of trapping and skinning
foxes (without personal protective equipment) and a cumula-
tive harvest of over 3,000 foxes. During a human rabies out-
break investigation in the Department of Amazonas in Perú
in 1990, 17% (8 of 48) of persons in two affected communities
were seropositive for rVNA, one of whom later died.14 In the
study by Lopez and others,14 the median rVNA titer among
the seven surviving persons was 0.18 IU mL−1 (range = 0.14–
0.66 IU mL−1), whereas the person who died had a titer of
Table 4
Risk factors for exposure to rabies virus among respondents in two communities in the Province Datem del Marañón of Perú, 2010
Subcategory
Seropostive Seronegative Total
P value OR (95% CI)n Percent n Percent n Percent
Demographics (N = 57)
Age less than or equal to 29 years* 1 11.1 29 60.4 30 52.6 0.010{ 0.08 (0.01–0.71)
Male 7 77.8 30 62.5 37 64.9 0.471 2.10 (0.39–11.23)
Santa Marta resident 7 77.8 31 64.6 38 66.7 0.703 1.92 (0.36–10.29)
Household characteristics
More than five people living in household (N = 57) 6 66.7 28 58.3 34 59.6 0.726 1.43 (0.32–6.40)
Own pets/livestock (N = 56) 7 77.8 43 91.5 50 89.3 0.244 0.33 (0.05–2.13)
Own dogs (N = 56) 2 22.2 18 38.3 20 35.7 0.466 0.46 (0.09–2.46)
Any pets/livestock bitten by bats (N = 49) 6 85.7 29 69.0 35 71.4 0.656 2.69 (0.29–24.66)
Activities
Lived in this house 1 year or less (N = 52) 1 12.5 11 25.0 12 23.1 0.663 0.43 (0.05–3.88)
More than 5 years living/working with bats (N = 41) 2 40.0 9 25.0 11 26.8 0.598 2.00 (0.29–13.94)
Reported hunting bats (N = 52) 2 25.0 4 9.1 6 11.5 0.227 3.33 (0.50–22.33)
Reported agriculture (N = 52) 8 100.0 39 88.6 47 90.4 1.000 NA‡
Reported using a mosquito net (N = 52) 1 12.5 14 31.8 15 28.8 0.412 0.31 (0.03–2.73)
Education (N = 52)
Secondary or above 2 25.0 10 22.7 12 23.1 1.000 1.13 (0.20–6.51)
Knowledge (N = 52)
Reported having basic or no rabies knowledge 8 100.0 44 100.0 52 100.0 NA NA
Indicated animal bites as mechanism of transmission 3 37.5 11 25.0 14 26.9 0.666 1.80 (0.37–8.79)
Described rabies as severe 4 50.0 19 43.2 23 44.2 1.000 1.32 (0.29–5.95)
Identified bats as a rabies source 6 75.0 35 79.5 41 78.8 1.000 0.77 (0.13–4.48)
Identified dogs as a rabies source 3 37.5 19 43.2 22 42.3 1.000 0.79 (0.17–3.72)
If bitten by a bat (N = 52)
Wash with soap and water 0 0.0 4 9.1 4 7.7 1.000 NA
Seek medical care 2 25.0 11 25.0 13 25.0 1.000 1.00 (0.18–5.70)
Do not know or do nothing 4 50.0 23 52.3 27 51.9 1.000 0.91 (0.20–4.12)
Other 2 25.0 6 13.6 8 15.4 0.593 2.11 (0.34–12.99)
If bitten by a rabid animal (N = 52)
Wash with soap and water 0 0.0 2 4.5 2 3.8 1.000 NA
Seek medical care 3 37.5 19 43.2 22 42.3 1.000 0.79 (0.17–3.72)
Do not know or do nothing 5 62.5 23 52.3 28 53.8 0.711 1.52 (0.32–7.16)
Bat exposure
Individuals with one or more bat exposures§ (N = 57) 9 100.0 36 75.0 45 78.9 0.180 NA
Bite (N = 57) 7 77.8 31 64.6 38 66.7 0.703 1.92 (0.36–10.29)
Bat bite more than one time per year (N = 38) 2 28.6 10 32.3 12 31.6 1.000 0.84 (0.14–5.10)
Bite within the last 6 months (N = 38) 5 71.4 19 61.3 24 63.2 1.000 1.58 (0.26–9.48)
Contact with unprotected skin (N = 57) 5 55.6 16 33.3 21 36.8 0.266 2.50 (0.59–10.61)
Skin contact more than one time per year (N = 20) 1 20.0 6 40.0 7 35.0 0.613 0.38 (0.03–4.23)
Skin contact within the last 6 months (N = 21) 2 40.0 9 56.3 11 52.4 0.635 0.52 (0.07–4.00)
Scratch (N = 57) 0 0.0 3 6.3 3 5.3 1.000 NA
Inside a bat cave or refuge (N = 57) 1 11.1 7 14.6 8 14.0 1.000 0.73 (0.08–6.80)
Ate or cooked a bat as food (N = 57) 0 0.0 0 0.0 0 0.0 NA NA
Vaccinated against rabies (N = 57)
Post-exposure prophylaxis (bat exposure) 1 11.1 0 0.0 1 1.8 0.158 NA
Pre-exposure prophylaxis (military service) 0 0.0 1 2.1 1 1.8 1.000 NA
*Mean age of population evaluated serologically.
{Statistically significant.
‡NA = not applicable.
§Defined as a bat bite, bat scratch, or bat contact with unprotected skin.
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7.6 IU mL−1 at the time of sampling. Because the study by
Lopez and others14 did not detect a statistical relationship
relating to age of the individuals or exposure to bats with
antibody concentration, all of the positive rVNA titers among
the seven survivors were considered to be nonspecific. Despite
potential for low-titer, false-positive neutralizing antibody titers
resulting from nonspecific inhibition of virus growth, a recent
review did not suggest evidence of nonspecific inhibition of
virus growth at serum dilutions of 1:25 or greater in serologi-
cal neutralization assays, although they were based on obser-
vations among non-indigenous persons.45 In the current study,
a 50% reduction of fluorescing fields at a 1:25 serum dilution
would have resulted in a titer of 0.2 IU mL−1, and given that
six of seven rVNA titers were greater than 0.2 IU mL−1, these
data do not suggest a high potential for nonspecific inhibition.
The single respondent with an rVNA titer below 0.2 IU mL−1
(and RNP IgG titer of 1:8) in this study also reported a history
of vaccination (Table 1), which is a more parsimonious expla-
nation for her seropositive status. It is also noteworthy that
none of the respondents in either community (seropositive or
otherwise) reported the preparation or consumption of bats as
a food source.
The observation of unvaccinated seropositive respondents,
in the context of a self-reported history of bat bites in an area
endemic for vampire bat rabies, suggests that RABV expo-
sure is not invariably fatal in humans. A genetic basis for
susceptibility and immunological response to rabies has been
shown previously in mice.46–48 Although it is possible that
certain isolated and remote populations in the Amazon region
may be genetically and immunologically unique,49,50 two stud-
ies have also found signatures of gender-specific genetic
admixture in certain Amazon populations and suggest that
historical social policies have strongly influenced the migra-
tion of persons to and genetic mixing within the Amazon
region.49,51 Genetic comparisons of immunological markers
and relevant inducible responses (e.g., humoral and cellular
response to rabies vaccination)52 from populations in urban
areas and throughout the Amazon region of Perú may shed
additional light on whether certain indigenous populations
show evidence of natural selection for enhanced nonspecific
or specific immunological responses and genetic resistance to
rabies infection.
Individual immune response to natural infection with
RABV may include virus-specific binding and neutralizing
antibodies depending on factors such as viral dose, degree of
replication in the periphery, and successful entry and replica-
tion in the central nervous system (CNS). Both RABV anti-
bodies to the glycoprotein and RNP have a proven role in
the immune response after vaccination.53,54 Based on patient
histories in the United States, RABV RNP binding anti-
bodies are typically detected first by IFA in response to
clinical infection, and rVNA may or may not be induced.38
These observations suggest an early response of antibodies to
RNP relative to the induction of rVNA during CNS infec-
tion. Based on the degree of peripheral replication, there
may be infected cells and budding of intact virions or apo-
ptosis of infected cells presenting RNP. Although the data
presented in this study cannot conclusively differentiate
between scenarios of abortive peripheral viral infection or
clearance of a small viral dose insufficient to establish infec-
tion, the seropositive responses show exposure to RABV in
the absence of vaccination.
The presence of rVNA in unvaccinated subjects implies
prior viral exposure but not necessarily viral replication,
which can be shown by the induction of rVNA responses to
even a single dose of inactivated rabies vaccine.55 However,
given that rabies vaccination is accomplished with large doses
of purified inactivated RABV virions, it remains unclear
whether replication is a prerequisite for induction of humoral
or cellular responses to natural exposures involving smaller
doses of street RABV. In an experimental infection of bats
with varying doses of RABV, low-dose RABV exposures did
not lead to productive CNS infection, and apparently, they
were cleared by an immune response in the periphery.56 Pre-
vious studies have shown that RABV-specific antibodies are
not uniformly induced in the serum or cerebrospinal fluid
(CSF) of clinical human rabies cases who do not receive
rabies vaccine or immune globulin treatment, with greater
probabilities of serological detection in patients with longer
morbidity periods (i.e., days alive after onset of clinical
symptoms).57–59 This report identifies a higher risk for bat
exposure among young persons, despite finding a greater risk
of rabies virus exposure (i.e., seropositive status) among
older persons. It is plausible that multiple low-dose RABV
exposures are needed to induce the rVNA responses
observed in this study, consistent with the observed correlation
of seropositive status with age. Evidence of RABV-specific
antibodies in serum and CSF of subjects who did not receive
rabies vaccine or immune globulin has been interpreted as
evidence of viral replication and an abortive infection.33,38
The data in this study are inconclusive with regard to abor-
tive infection in the seropositive respondents, because CSF
samples were not collected, thus precluding evidence of
RABV invasion into the CNS. Responses to interview ques-
tions about prior or current illness (and associated symp-
toms) did not support a history of CNS infection among
respondents in this study.
Innate immunity is typically another important component
in combating viral infections. Prior studies have suggested
that street RABVs tend to evade induction of the host innate
immune response and particularly, interferon and inflamma-
tory pathways.60 This finding is consistent with the observa-
tions of an inverse relationship between RABV virulence and
the degree of viral replication, with highly pathogenic RABVs
showing limited levels of replication, G protein accumulation,
and apoptotic signaling in infected neurons.61,62 Although one
study showed that a bat (street) RABV replicates efficiently
in nonneuronal cells,63 it has been suggested that limited rep-
lication in the periphery may be an adaptation of highly
neuroinvasive street RABVs to minimize a peripheral host
immune response in vivo, thus facilitating entry into the
CNS.61 Minimal immune induction in the periphery may be
expected under scenarios of successful street RABV infec-
tion (i.e., CNS invasion); however, none of the respondents
reported symptoms suggestive of CNS involvement.
Rather than invoking peripheral viral replication as a req-
uisite to the induction of rabies-specific serum antibody, one
could also consider a dirty bite hypothesis. Little is known
about (1) the population of RABV particles transmitted in
the saliva during an animal bite and (2) what other sub-
stances or organisms may also be present. It is unrealistic
to assume that homogenous populations of completely
intact RABV virions are passed in the saliva, particularly
given reports of defective interference (DI) particles.64
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Furthermore, it cannot be ruled out that there are other
properties or normal flora organisms associated with saliva
from an animal bite that contribute to induction of a
nonspecific innate and inflammatory immune response to
the wound in the absence of peripheral RABV replication.
These data highlight important complexities concerning the
interpretation of serology, which is currently the only diag-
nostic tool that has been successful in antemortem diagnosis
of nonfatal cases of human rabies infection.
Prior vaccination history could confound the interpretation
of the serological data in this study. Human rabies cell cul-
ture and nerve tissue vaccines are inactivated and do not rep-
licate in recipients,65 but they induce robust rVNA responses.66,67
Equivocal evidence has been published regarding induction
of non-neutralizing RNP antibody after rabies vaccination.59,68,69
It is notable that suckling mouse brain vaccine (SMB) is
used in Perú for rabies PreEP and PEP, although PreEP is
typically restricted to persons at occupational risk of infec-
tion. Only one seropositive respondent reported receiving
rabies PEP. Data were unclear regarding self-reported pro-
phylaxis among two other respondents. Given the remote
location of these villages, our collaboration with personnel
from the nearest health post that would have administered
PEP during an intervention and the vaccination history
reporting among other respondents, it is unlikely that the
other eight seropositive respondents received rabies PreEP
or PEP. Furthermore, persons living in this region often do
not understand the real significance of being bitten by a
vampire bat and are unlikely to seek medical assistance after
a bite or may actively avoid modern medical care because of
traditional beliefs.70
Prior reports of human rabies outbreaks in the Amazon,
including 11 cases in the Department of Loreto in Perú in
1995, the results of this study, and nearby recent vampire bat-
associated outbreaks suggest a high rabies risk in the Peruvian
Amazon (Figure 1).12,15 Vampire bats principally feed on cat-
tle or other mammals (including humans) when livestock is
not widely available.71,72 Seasonal incidence of RABV infec-
tions from vampire bats to humans and cattle occurs pur-
portedly shortly after the onset of the rainy season.14,73,74
However, reports of outbreaks during the dry season also
exist.75,76 Regardless of season, several reports indicate stron-
ger coincidence of vampire bat depredation on humans after
the elimination of livestock, such as pigs or cattle.14,74,77 In the
current study, despite the observation that nearly equal pro-
portions of exposed and non-exposed respondents reported
owning pets or livestock (Table 2), exposed persons were
more likely to report that their pets or livestock had been
bitten by bats, presumably with greater risk when the bitten
animals are confined close to one’s residence. Interestingly,
Santa Marta respondents exhibited nearly a ninefold greater
risk for bat exposure, which may be non-exclusively influenced
by other identified risk factors in the survey, including a greater
proportion of younger persons and greater proportion of pets
or livestock bitten in Santa Marta (Table 1). However, other
factors not captured in the survey may also contribute to this
observation, such as the absence of cattle in Santa Marta,
asymmetry in the proximity of bat roosts to these communities,
or some other unique ecological feature, although it is relevant
to note that a greater proportion of Truenococha respondents
reported entering a bat refuge (Table 1). Greater household
size also contributed to increased risk for bat exposure, and it is
possible that larger families have a greater proportion of young
children, leading to greater risk of bat exposure. It is clear that
there are a variety of factors that can influence individual and
household risk of bat exposure in this region. Greater replica-
tion and geographic representation of communities in the
Amazon would identify the most robust factors that contribute
to geospatial variation in risk for bat and RABV exposure.
Through evidence presented in this study and one earlier
report,14 it is evident that a substantial fraction of the human
population living in remote areas of the Peruvian Amazon
experiences regular depredation by vampire bats and likely
exposure to RABV. Seasonal patterns of vampire bat depre-
dation in this region of the Amazon have not been well-
characterized, and the majority of persons interviewed did
not identify any apparent seasonality. Regardless, it is plau-
sible that some individuals experience nonfatal exposure to
RABV by vampire bat bites, with subsequent exposures
leading to an immunological boost or anamnestic response.
Regardless, all persons living in these communities should be
considered for rabies prophylaxis as part of any subsequent
intervention. New paradigms, such as rabies PreEP for
Amazon populations at risk, may be necessary to prevent
and control rabies in such unique ecological circumstances.
In closing, it is relevant to recognize that the number of
newly discovered lyssaviruses has increased significantly in
recent decades. Pre-1980, traditional nomenclature recog-
nized just four Lyssavirus genotypes (i.e., RABV, Lagos bat
virus [LBV], Duvenhage virus [DUVV], and Mokola virus
[MOKV]), whereas there are now 12 recognized species
within the genus, 11 of which are presumed to have bats as
the primary reservoir host.78 Although earlier studies ques-
tioned the pathogenicity of certain subsets of lyssaviruses,
namely the phylogroup 2 viruses (e.g., LBV and MOKV),79
experimental studies have shown that phylogroups 1 and
2 lyssaviruses are pathogenic in animal models, including
bats,80–83 and human infections with phylogroups 1 and
2 lyssaviruses are reviewed in the work by Banyard and
others.84 The absence of human infections linked to certain
lyssaviruses need not be misinterpreted as variation in patho-
genicity of those lyssaviruses for three reasons: (1) a near
absence of any systematic surveillance system for reporting
and detecting human rabies infections in many parts of the
world where these viruses are endemic,85 (2) the overwhelm-
ing burden of canine-associated human RABV infections
in many of these same places (i.e., throughout Africa and
Central and Southeast Asia), which could obscure less fre-
quent bat-associated infections,1 and (3) the excellent sensi-
tivity of the current gold standard fluorescent antibody test to
detect any lyssavirus infection but inability of this test to type
the specific lyssavirus implicated in infection. Although it is
likely that there are undiscovered lyssaviruses in the Old
World (figure 1b in the work by Rupprecht and others78),
RABV is the only lyssavirus known to be present in the New
World. After the advent and transfer of technologies such as
monoclonal antibody typing and nucleic acid detection and
sequencing methods throughout the Americas and along with
regional campaigns for canine rabies elimination in the
Americas and increased characterization of human rabies
infections to achieve this goal, there still have not been any
new lyssaviruses discovered in the Americas.5,11,86,87 For these
reasons, a hypothesis that the results in this study reflect
cross-reactivity to an undiscovered lyssavirus is one for which
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evidence is lacking but is also not an explanation that can be
ruled out. However, hypotheses that there are undiscovered
and non-pathogenic lyssaviruses that could be implicated as a
mechanism for non-lethal rabies exposure showed in this study
seem unsubstantiated based on evidence of lyssavirus patho-
genicity in humans and animals worldwide.
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